PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases - GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases - Takeda.com
GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases

 

NewswireToday - /newswire/ - Chalfont St Giles, United Kingdom, 2014/11/11 - GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases - Takeda.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Worldwide trends of aging populations and less healthy lifestyle habits, are contributing to the rise of non-alcoholic fatty liver disease (NAFLD) 1;
• More than 100 million people are estimated to be suffering from NAFLD (15% to 20% of the populations of advanced industrial nations) 2;
• This alliance is key to enabling the early development of therapeutic drugs through the use of a minimally invasive diagnostic technology.

This announcement coincides with AASLD, the 65th Annual Meeting of the American Association for the Study of Liver Diseases, held from 7-11 November in Boston, MA, USA.

Liver disease has almost no visible symptoms, and its progress is characterized by a hardening of the tissues due to fibrosis accompanying the inflammation of the liver and a worsening of symptoms due to cirrhosis. Amid such worldwide trends of recent years as the aging population and less healthy lifestyle habits, non-alcoholic fatty liver disease (NAFLD) has emerged as a type of metabolic syndrome.

Over the past couple of decades, NAFLD and non-alcoholic steatohepatitis (NASH) have become the number one cause of liver disease in developed countries.1 The prevalence of NAFLD has doubled during the last 20 years, whereas the prevalence of other chronic liver diseases has remained stable or even decreased. More recent data confirm that NAFLD and NASH play an equally important role in developing regions like the Middle East, Far East, Africa, the Caribbean, and Latin America.2 Early diagnosis of hepatic fibrosis as well as the development of drugs to control the progression of liver disease has become important issues.

According to the alliance agreement, GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the research and development work Takeda is conducting on liver diseases. By optimizing the strengths of both companies in the alliance, the collaborative effort aims to help develop therapeutic drugs as well as new diagnostic technologies for liver diseases.

Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy, in which a needle is inserted through the skin into the liver, a sample of which is then removed for measurement. With MR elastography commercialized by GE Healthcare, in use in the United States since 2009 and in Japan since 2012, it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner. It is expected that this kind of GE Healthcare diagnostic technology will contribute to Takeda's efforts to develop innovative medicines.

“It gives me great pleasure to have been able to build this alliance with GE Healthcare to develop therapeutic drugs to treat liver diseases,” said Tadataka Yamada, Chief Medical & Scientific Officer at Takeda. “This alliance will assist efforts to develop new therapeutic options that ease the burden on the patient. Moving forward, we will continue to put the patient first and incorporate a wide range of innovations into the field of drug discovery.”

“It is extremely gratifying to me that, through this collaboration, our technologies will be of use in the development of treatments for the liver diseases that are of particular importance not just in Asia, but worldwide,” said Akihiko Kumagai, Chairman of GE Healthcare Japan with overall responsibility for liver disease programs. “We have been focusing efforts on developing technologies to help provide solutions for liver cancer. As one location in our global research and development network, Japan, whose strategy is to create solutions for an aging population, has been a driving force behind these efforts. Innovations by GE will continue to contribute to the health of people all around the world.”

About the agreement
Details about the terms of the agreement including financial stipulations are not being disclosed. The contract pertains to an alliance involving diagnoses in the development of therapeutic drugs for liver disease.

About MR elastography
MR elastography is a technology in which MRI is used to generate images depicting the elasticity of the body’s internal tissues based on pulses administered externally. The main characteristic of the technology is its ability to distinguish and differentiate by color the relative stiffness of tissue. Measurement data acquired from the region of interest (ROI) defined for an image reflect the relative stiffness (elasticity) of the liver. Clinically, the technology holds promise for potentially aiding in the assessment of liver disease amid the uptrend in liver disease accompanying the ongoing aging trend in Japan's population.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (takeda.com) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

Contacts
GE Healthcare Japan Corp.
Communications Department
P: +81-120-202-02

Takeda Pharmaceutical Company Limited
Corporate Communications Department (PR)
P: +81-3-3278-2037

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE News Center | Takeda Pharmaceutical
Publisher Contact: Will Spiers - GE Healthcare 
+44(0)14 9454 5278/ +44(0)79 7127 6757 william.spiers[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)